Superparamagnetic Iron Oxide Tracer: A Magnetic Match to Gold Standard in Melanoma Sentinel Lymph Node Biopsy-A Systematic Review and Meta-Analysis.

Superparamagnetic iron oxide (SPIO) tracer is a potential option for sentinel lymph node biopsy (SLNB), though its application in melanoma remains minimally explored. This systematic review evaluated the use of SPIO tracer compared to the standard approach for SLNB in melanoma. SPIO demonstrated comparable efficacy and detection rate to the gold standard, with a sensitivity of 94%.

Exceptional Response to Immunotherapy-based Treatment in Compound -Mutated Oligometastatic Pulmonary Sarcomatoid Carcinoma: A Case Report.

Pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subtype of non-small cell lung cancer (NSCLC) with limited treatment options and poor prognosis. mutations generally respond to tyrosine kinase inhibitors (TKIs)-based targeted therapy but are typically associated with resistance to immunotherapy. We report a case of oligometastatic PSC harboring compound mutations (p.

Gender-affirming healthcare in the Nordic countries: An overview.

This narrative review examines gender-affirming healthcare in the Nordic countries, highlighting historical developments, legal frameworks, epidemiological trends, and current clinical practices. Transgender healthcare dates back to the early 20th century and gained international attention in the early 1950s following one of the first widely publicized gender-affirming surgeries performed in Denmark. Since then, care models have evolved, supported by policy, research, and clinical practice across Europe and North America.

Diagnostic and therapeutic appropriateness in different stages of esophageal/GEJ cancers. The FICOG project.

Background: Esophageal cancer is a rare neoplasm, with more than 0.6 million new cases and 0.54 million deaths worldwide in 2020.

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial.

Background: The PORTEC-3 trial investigated the benefit of chemoradiotherapy versus pelvic radiotherapy alone for women with high-risk endometrial cancer. We present the preplanned long-term analysis of the randomised PORTEC-3 trial with a post-hoc analysis including molecular classification of the tumours.

Methods: PORTEC-3 was an open-label, multicentre, randomised, international phase 3 trial.

Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma.

Epcoritamab is a subcutaneous CD3xCD20 bispecific antibody approved as monotherapy for relapsed/refractory (R/R) follicular lymphoma (FL). We evaluated fixed-duration epcoritamab with rituximab plus lenalidomide (R2) in R/R FL in arm 2 of EPCORE® NHL-2 (phase 1b/2; NCT04663347). Patients received epcoritamab (2 step-up doses, then 48-mg full doses) for up to 2 years and R2 for up to 12 cycles (28 days/cycle).

Liquid biopsy- A pivotal test to help navigate clinical decisions at a precision center in India!

Liquid biopsy, specifically circulating tumor DNA (ctDNA) analysis, has emerged as a transformative tool in precision oncology, providing real-time, minimally invasive characterizations of the tumor and tumor dynamics. While tissue biopsy is a critical tool for baseline diagnosis of malignancy, it is often limited by sampling constraints and an inability to capture tumor heterogeneity. In this study, we explored the clinical utility of serial ctDNA testing in guiding therapeutic decisions across a cohort of 30 patients with diverse solid tumors.

Genome topology analysis and transcriptomics of human osteoclasts reveals enhancer-promoter interactions at loci for bone traits and diseases.

Genome-wide association studies (GWAS) relevant to osteoporosis have identified hundreds of loci; however, understanding how these variants influence the phenotype is complicated because most reside in non-coding DNA sequence that serves as transcriptional enhancers and repressors. To advance knowledge on these regulatory elements in osteoclasts (OCs), we performed Micro-C analysis, which informs on the genome topology of these cells and integrated the results with transcriptome and GWAS data to further define loci linked to BMD. Using blood cells isolated from 4 healthy participants aged 31-61 yr, we cultured OC in vitro and generated a Micro-C chromatin conformation capture dataset.

Serum Pepsinogen as a Biomarker of Gastrointestinal Stromal Tumors (GIST) in Stomach.

Background: Gastric GISTs (GG) are significant mesenchymal tumors. No biomarker has been identified for GG detection. We first observed mucosal atrophy surrounding GG tumors, leading to the hypothesis that localized atrophy may alter serum pepsinogen (PG) levels.

The progressively exhausted T cell response to a poorly immunogenic model of HCC can be partially rescued by immune checkpoint blockade and is heavily suppressed by T cell responses to oncolytic virotherapy.

Currently, the benefits of Immune Checkpoint Blockade (ICB) for Hepatocellular carcinoma (HCC) are restricted to a subset of patients. We hypothesized that co-treatment with the inflammatory oncolytic virus (OV) Vesicular Stomatitis Virus (VSV-IFNβ) would reprogram the highly immunosuppressive Tumor Microenvironment (TME) to enhance ICB. However, VSV-IFNβ inhibited the efficacy of ICB.

Case report of isolated aortic valve AL-amyloidosis following aortic valve replacement.

Background: Light chain (AL)-amyloidosis is a haematologic malignancy where cardiac involvement confers a worse prognosis. There is a recognized association between aortic stenosis (AS) and transthyretin amyloidosis (ATTR) cardiomyopathy. However, there is no such reported association with AL amyloidosis.

A population-based analysis of patterns of care in patients with de novo muscle-invasive bladder cancer from Alberta, Canada.

Introduction: Approximately 25% of patients diagnosed with bladder cancer have muscle-invasive disease (MIBC). While real-world data have highlighted opportunities to improve curative-intent treatment rates, comprehensive population-level data in Canada are limited. This study aimed to assess patterns of care and outcomes in a real-world cohort of MIBC in Canada.

Exploiting viral infection/vaccination to focus high-affinity T cell populations into tumors using oncolytic viro-immunotherapy.

Immune tolerance restricts the number of T cells with significant affinity for self-tumor-associated antigens (TAAs), thereby limiting successful cancer immunotherapy through an inability to generate populations of high-affinity anti-tumor T cells. In contrast, viral infection/vaccination primes and expands high-affinity effector and memory T cells against viral antigens. We show here that it is possible to exploit population-wide preexisting, anti-viral memory recall responses against SARS-CoV-2 antigens to focus a high-affinity, immunodominant T cell response into tumors by oncolytic virus (OV)-mediated or chimeric antigen receptor (CAR)-mediated delivery of viral antigens that are not themselves related to TAAs.

Evaluating the Effect of a Sleep Prehabilitation Intervention in Patients Awaiting Elective Surgery: Protocol for a Single-Blind Randomised Trial.

Adequate sleep health is critical for surgical recovery. Disrupted sleep can impede wound healing and cognitive performance and contribute to poor surgical outcomes. Preoperative intervention aimed at improving surgical outcomes is often referred to as prehabilitation and commonly uses exercise, nutrition or psychological intervention.

Catheter Ablation for Atrial Fibrillation in Breast Cancer Survivors: An Exploratory Observational Study Using the French Nationwide Health Care Database Sample.

Background: Catheter ablation is a key treatment for atrial fibrillation (AF). This procedure is clearly identifiable in French medical-administrative databases and can be used as a surrogate for symptomatic patients with drug-refractory or symptomatic paroxysmal AF forms. Breast cancer (BC) patients have an increased risk of AF, but knowledge about AF forms treated by ablation is limited.

The age of fit-equity: ignoring age and fitness in treatment selection for chronic lymphocytic leukemia.

Not available.

Uterine Sarcomas with Recurrent KDM2B Gene Fusions: Three Cases of a Possible Novel Subtype of High-Grade Endometrial Stromal Sarcoma.

The advent of widespread genomic testing of uterine mesenchymal tumors has led to novel insights into the biology of these diverse tumors, and many genomically-defined entities have been described in recent years. During a larger study of endometrial stromal sarcomas and unclassified uterine sarcomas, we identified three tumors harboring KDM2B gene fusions. Patients were 32, 61, and 67 years old and all initially underwent incomplete sampling via laparoscopic myomectomy (n=1), laparoscopic biopsy (n=1), or hysteroscopic myomectomy (n=1).

Joint Metabolomics and Transcriptomics Reveal Rewired Glycerophospholipid and Arginine Metabolism as Components of BRCA1-Induced Metabolic Reprogramming in Breast Cancer Cells.

: The breast cancer susceptibility gene 1 () is a tumor suppressor gene whose mutations are associated with increased susceptibility to develop breast or ovarian cancer. mainly exerts its protective effects through DNA double-strand break repair. Although not itself a transcriptional factor, BRCA1, through its multiple protein interaction domains, exerts transcriptional coregulation.

Practical Guidance for the Expanded Implementation and Provision of Bispecific Antibodies for Diffuse Large B-Cell Lymphoma (DLBCL) Across Canada.

(1) Background: Bispecific antibodies (BsAbs) for the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) can be delivered in ambulatory healthcare settings; however, the safe and effective management of potential side effects, such as cytokine release syndrome (CRS), requires protocolized monitoring and management. (2) Methods: An Expert Working Group (EWG) of nine hematologists from across Canada, with experience in leading BsAb program implementation, combined a review of published literature, a comparison of national/provincial/regional guidance documents and protocols, and their professional experiences to produce an informed framework for BsAb program implementation in various healthcare settings. (3) Results: The EWG supports and recommends the progression of BsAb provision from predominantly inpatient hospital settings to community/ambulatory care settings closer to the patient's home.

BCMA CAR-T: From Multiple Myeloma to Light-Chain Amyloidosis.

Light-chain (AL) amyloidosis is a rare clonal plasma cell disorder that, if left untreated, carries a high risk of organ damage and mortality. Due to the rarity of the disease and the vulnerability of affected organ systems, treatment requires significant caution and nuance. As a plasma cell dyscrasia, AL amyloidosis treatment regimens are often adapted from those used for related disorders, particularly multiple myeloma.

Geographic access to radiotherapy services in Canada.

Purpose: The vast geography and sparse population of Canada pose substantial challenges to delivering radiotherapy services. In this cross-sectional study, we sought to characterize the geographic accessibility of radiotherapy in Canada and investigate where future radiotherapy facilities can be optimally located.

Methods And Materials: Demographic and human geographic data were extracted from the 2021 Canadian Census for 57,937 dissemination areas (geographically stable regions of approximately 500-700 persons), and active facilities providing megavoltage external beam radiotherapy were located using national and international directories.

Mesothelin-directed protein-drug conjugates for mesothelin-low solid tumor therapy.

Mesothelin (MSLN) is an attractive therapeutic target for precision cancer treatments. However, MSLN can be cleaved and shed from tumor cells, resulting in the presence of soluble MSLN (sMSLN), which significantly hinders the efficacy of MSLN-targeted therapies. Here, we identify a MSLN-targeting designed ankyrin repeat protein (DARPin) M7, which specifically binds to the protease-sensitive C-terminal region of MSLN.